ESC Premium Access

Does the risk for heart failure (HF) modulate the effectiveness of empagliflozin on HF hospitalisation or CV death in patients with type 2 diabetes without HF? Insights from EMPA-REG OUTCOME

Congress Presentation

About the speaker

Professor Javed Butler

Baylor Scott and White Health, Dallas (United States of America)
105 presentations
14 followers

5 more presentations in this session

Heart failure and death in new users of SGLT2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups in 4 countries and >270,000 patients: The CVD-REAL Study

Speaker: Professor A. Norhammar (Stockholm, SE)

Thumbnail

Efficacy of beta-blockers in heart failure according to left ventricular ejection fraction: An individual patient level analysis of double-blind randomised trials

Speaker: Professor D. Kotecha (Birmingham, GB)

Thumbnail

Marked variation in the efficacy of beta-blockers across cardiovascular health: A Global systematic assessment of mortality, myocardial infarction and stroke

Speaker: Doctor O. Ziff (Birmingham, GB)

Thumbnail

Heart Failure-Wii study

Speaker: Professor T. Jaarsma (Linkoping, SE)

Thumbnail

Predicting right heart failure after implantation of continuous flow left ventricular assist devices (EUROMACS-RHF) score: analysis of the EUROMACS data

Speaker: Professor O. Soliman (Galway, IE)

Thumbnail

Access the full session

Late-Breaking Science in Heart Failure

Speakers: Professor J. Butler, Professor A. Norhammar, Professor D. Kotecha, Doctor O. Ziff, Professor T. Jaarsma...
Thumbnail

About the event

Image

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb